Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on World Healthcare Report.
Press releases published on May 6, 2025
VAXIL: SHARE CONSOLIDATION
GlobeNewswire
·
May 6, 2025
Not for distribution by US newswire or in United States TORONTO, May 06, 2025 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), is pleased to make the following updates regarding the Company’s activities. Vaxil announces …
Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Financial Results on Tuesday, May 13, 2025
GlobeNewswire
·
May 6, 2025
NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, …
Altimmune to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025
GlobeNewswire
·
May 6, 2025
GAITHERSBURG, Md., May 06, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2025 financial results on Tuesday, May 13, 2025. Altimmune management …
OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights
GlobeNewswire
·
May 6, 2025
-- Continued progress in the PIKture-01 trial; on track to report additional data in the second half of 2025, including mature single agent and initial combination data -- Expansion of the Company’s PI3Ka franchise with the planned announcement of a pan- …
Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress
GlobeNewswire
·
May 6, 2025
- Favorable clinical data in PD-(L)1 resistant patients - - Dose expansion enrollment complete with full data expected by year-end 2025 - - Cash runway into the second quarter of 2026 - BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. …
Kura Oncology to Participate in Bank of America Securities Healthcare Conference
GlobeNewswire
·
May 6, 2025
SAN DIEGO, May 06, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in Bank of …
CorMedix Inc. Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 6, 2025
‒ Q1 2025 Net Revenue of $39.1mm; Adjusted EBITDA of $23.6mm ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time BERKELEY HEIGHTS, NJ., May 06, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on …
Zevra Therapeutics Announces Details for Q1 2025 Financial Results Call
GlobeNewswire
·
May 6, 2025
CELEBRATION, Fla., May 06, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced it will report corporate …
Bioventus Reports First Quarter Financial Results
GlobeNewswire
·
May 6, 2025
Q1 reported revenue of $123.9 million declined 4.3%; Organic* revenue advanced 5.0% First quarter net loss was $0.04 per share compared to a loss of $0.08 in the prior-year period Non-GAAP earnings* of $0.08 per share increased 33% Company reiterated …
Nitric Boost Ultra Reviews And Complaints (INVESTIGATED) What You Need to Know Before Buying This Male Performance Booster!
GlobeNewswire
·
May 6, 2025
ALBANY, N.Y., May 06, 2025 (GLOBE NEWSWIRE) -- Let’s be honest—most guys have seen those supplements that promise the world: more energy, better circulation, improved stamina, and a stronger bedroom performance. They all start to sound the same after a …
Neuronetics Reports First Quarter 2025 Financial and Operating Results
GlobeNewswire
·
May 6, 2025
MALVERN, Pa., May 06, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ: STIM) (the “Company” or “Neuronetics”) a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of …
Sanofi: Investing in prevention builds Europe’s health and competitiveness
GlobeNewswire
·
May 6, 2025
WARSAW, Poland, May 06, 2025 (GLOBE NEWSWIRE) -- As the Polish Presidency of the EU Council enters its final stage health policy remains central to Europe’s strategic agenda. At the European Economic Congress in Katowice, discussions reflected both the …
Kraig Biocraft Laboratories Successfully Completes March/April Production Cycle; May Production Now Underway
GlobeNewswire
·
May 6, 2025
ANN ARBOR, Mich., May 06, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or "Kraig Labs"), a world leader in spider silk technology*, announces that it has successfully completed its March/April spider silk …
Y-mAbs to Announce First Quarter 2025 Financial and Operating Results on May 13, 2025
GlobeNewswire
·
May 6, 2025
PRINCETON, N.J., May 06, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody- …
The Joint Corp. Strengthens Management Appointing SVP Legal and SVP Operations and Patient Experience
GlobeNewswire
·
May 6, 2025
- Franchising legal specialist Andra J. Terrell with 20 years of experience in global master, single-unit and multi-unit franchising; compliance strategy; and financing, mergers, acquisitions, and divestitures- - Franchise operations leader Eric Wyatt with …
Pasithea Therapeutics Reports Positive Pharmacodynamic Results Demonstrating Robust Target Engagement from its Ongoing Phase 1 Clinical Trial of PAS-004
GlobeNewswire
·
May 6, 2025
-- PAS-004 shows up to 91% inhibition of pERK, confirming substantial target engagement -- -- One patient in cohort 4A with stage 4 KRAS G12R mutated pancreatic cancer achieves over 5 months of stable disease with tumor volume reduction of -9.8% -- MIAMI, …
Mersana Therapeutics Announces Strategic Restructuring and Reprioritization Plan Focused on Advancing Emi-Le in Triple-Negative Breast Cancer
GlobeNewswire
·
May 6, 2025
Cost-saving initiatives expected to extend company’s cash runway and support current operating plan commitments into mid-2026 Company to host conference call at 8:00 a.m. ET on May 15 to discuss business updates and first quarter 2025 financial results …
Topas Therapeutics’ TPM502 Achieves Gluten-specific Tolerance Induction, Positive Safety Profile in Phase 2a Trial in Celiac Disease Patients
GlobeNewswire
·
May 6, 2025
TPM502 achieved significant and dose-dependent reduction in IL-2 and IFN-γ release by gluten-specific T cells and durable immunomodulation of gluten-specific CD4+ T cells Patient-reported outcomes indicated dose-dependent reduction of symptoms following a …
Optima Health to acquire Care first
GlobeNewswire
·
May 6, 2025
Optima Health to acquire Care first, a leading provider of mental health services, for a net consideration of £15,000, adding c.£3.7 million revenue to the Group Acquisition provides Optima with increased scale in its Mental Health division and will …
EnteroBiotix Presents Positive IBS-C Data at Digestive Disease Week® 2025
GlobeNewswire
·
May 6, 2025
EnteroBiotix Presents Positive IBS-C Data at Digestive Disease Week® 2025 EBX-102-02 was well tolerated and demonstrated clinically meaningful improvements across multiple symptom domains in IBS-C patients Ph2b trial in IBS-C initiating in H2 2025 to …